Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Dec;21(12):1630.
doi: 10.1016/S1473-3099(21)00693-9.

Assessing the evidence on remdesivir

Isaac Núñez  1 , Adrian Soto-Mota  2
Affiliations
Comment

Assessing the evidence on remdesivir

Isaac Núñez et al. Lancet Infect Dis. 2021 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

We declare no competing interests.

Comment on

References

    1. Ader F, Bouscambert-Duchamp M, Hites M, et al. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial. Lancet Infect Dis. 2021 doi: 10.1016/S1473-3099(21)00485-0. published online Sept 14. - DOI - PMC - PubMed
    1. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of COVID-19—final report. N Engl J Med. 2020;383:1813–1826. - PMC - PubMed
    1. US Food and Drug Administration FDA approves first treatment for COVID-19. Oct 22, 2020. https://www.fda.gov/news-events/press-announcements/fda-approves-first-t...
    1. Pan H, Peto R, Henao-Restrepo AM, et al. Repurposed antiviral drugs for COVID-19—interim WHO SOLIDARITY trial results. N Engl J Med. 2021;384:497–511. - PMC - PubMed
    1. Horby P, Lim WS, Emberson JR, et al. Dexamethasone in hospitalized patients with COVID-19. N Engl J Med. 2021;384:693–704. - PMC - PubMed

MeSH terms